Natural Compound

Lutein

β,ε-Carotene-3,3'-diol (Lutein)

Evidence TierAWADA NOT PROHIBITED

tuneTypical Dose

10-20 mg per day

watchEffect Window

3-6 months for meaningful MPOD increase. Ongoing protection with continued use.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lutein is a carotenoid concentrated in the macula and brain. It is used for eye health, visual performance, and as part of strategies to slow age-related macular degeneration progression.

Evidence shows lutein increases macular pigment and supports visual performance over time, especially when paired with zeaxanthin. A newer randomized trial in high screen users found objective improvements in tear metrics and photo-stress recovery, which modernizes lutein beyond the older AMD-only framing. Subjective eye-strain relief was less convincing than the objective ophthalmic improvements, so expectations should stay practical rather than dramatic.

Xanthophyll carotenoid that accumulates in the macula, filtering high-energy blue light and acting as a direct retinal antioxidant.

Outcomes

What This Is Expected To Influence

Primary Outcomes

Slows AMD progression when combined with zeaxanthin in AREDS2 formula
Increases macular pigment optical density (MPOD)

Secondary Outcomes

Improves contrast sensitivity and glare recovery
Emerging neuroprotective benefits for cognitive function

Safety

Contraindications and Interactions

Contraindications

None established

Side effects

Harmless skin yellowing (carotenodermia) at very high doses

Interactions

Orlistat/cholestyramine may reduce absorption
Beta-carotene competes for absorption

Avoid if

Smokers taking concurrent high-dose beta-carotene

Evidence

Study-level References

lutein-SRC-001Randomized double-blind placebo-controlled trial

Sourceopen_in_new

Lopresti AL, Smith SJ. The effects of lutein/ zeaxanthin (Lute-gen®) on eye health, eye strain, sleep quality, and attention in high electronic screen users: a randomized, double-blind, placebo-controlled study. Front Nutr. 2025;12:1522302. doi:10.3389/fnut.2025.1522302. PMID:39963662.

Population: Adults aged 18 to 65 using electronic screens more than 6 hours per day.

Dose protocol: 10 mg lutein plus 2 mg zeaxanthin-isomers daily for 6 months

Key findings: The 2025 randomized trial found better Schirmer tear testing, better tear-film break-up time, and faster photo-stress recovery in high screen users.

Notes: Self-reported eye strain did not separate as clearly from placebo, so objective eye-health framing is stronger than symptom-relief marketing.

Paper content

This 2025 randomized trial gives lutein and zeaxanthin a modern digital-eye-strain use case grounded in objective tests rather than marketing language. In high screen users, 10 mg lutein plus 2 mg zeaxanthin improved tear metrics and photo-stress recovery over 6 months, but self-reported symptom scores did not clearly separate from placebo. That supports a practical eye-health framing while avoiding exaggerated claims about immediate subjective relief.